AGAdam C. T. Gillman

Adam C. T. Gillman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Adam C. T. Gillman has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    In silico antigenic and vaccinological characterization of two production-optimized recombinant yellow fever virus envelope proteins

    by Elif Naz Bingöl, Gioacchin Iannolo, Rosaria Tinnirello, Adam C.T. Gillman, Jesús Reiné, Chiuan Yee Leow, Chiuan Herng Leow, Asif M. Khan, Ester Badami, Bruno Douradinha

  • Open Access

    In silico antigenic and vaccinological characterization of two production-optimized recombinant yellow fever virus envelope proteins

    by Elif Naz Bingöl, Gioacchin Iannolo, Rosaria Tinnirello, Adam Gillman, Jesús Reiné, Chiuan Yee Leow, Chiuan Herng Leow, Asif M. Khan, Ester Badami, Bruno Douradinha

    Yellow fever virus (YFV) remains a major public health threat in endemic regions of Africa and South America. Although the live-attenuated YFV 17D vaccine is highly effective, its use is contraindicated or requires careful risk assessment in some vulnerable populations, supporting the development of nonreplicating vaccine alternatives and improved antigenic tools. In this study, we performed an integrated in silico comprehensive characterization of two production-optimized recombinant YFV envelope (Env) proteins derived from the Asibi and 17D strains. Physicochemical, antigenicity, solubility, allergenicity, proteolytic-sensitivity, epitope-conservancy, structural-modeling, conformational B-cell epitope, molecular-docking, molecular-dynamics (MD), electrostatic-interface, and immune-simulation analyses were used to evaluate their structural and immunological properties. Both Env proteins were predicted to be antigenic, hydrophilic, structurally stable, and compatible with recombinant antigen development, although allergenicity predictions were partially discordant for the 17D-derived antigen. Epitope mapping identified multiple predicted CD8⁺ and CD4⁺ T-cell epitopes, conserved linear B-cell epitopes, and conformational antibody-accessible regions. Conservation analyses showed that many predicted T-cell epitopes were maintained across representative YFV strains, whereas predicted B-cell epitopes displayed greater strain-associated variability. Structural modeling suggested that both proteins can adopt native-like dimeric conformations, while molecular-docking and MD simulations with the neutralizing YFV antibody YD6 supported the preservation and stability of conformational surfaces compatible with antibody engagement. Immune simulations predicted coordinated adaptive responses after repeated immunization. Overall, these findings support further experimental evaluation of recombinant YFV Asibi Env and YFV 17D Env as nonreplicating vaccine antigens, diagnostic reagents, and tools for investigating YFV antigenicity and immune responses.

  • Open Access

    Epstein-Barr Virus Nuclear Antigen 3C Inhibits Expression of COBLL1 and the ADAM28-ADAMDEC1 Locus via Interaction with the Histone Lysine Demethylase KDM2B

    by Adam C. T. Gillman, Gillian Parker, Martin J. Allday, Quentin Bazot

    EBV is a virus associated with human cancers and is well known for its ability to transform B lymphocytes into continuously proliferating lymphoblastoid cell lines. EBNA3C is considered an oncoprotein and has been shown to be essential for B cell transformation by EBV. EBNA3C is well characterized as a viral transcription factor, but very little is known about its mechanisms of action. In the present study, we demonstrate that removal of the activating histone mark H3K4me3 and deposition of the repressive mark H3K27me3 by EBNA3C on COBLL1 are achieved by at least two distinct mechanisms. Furthermore, we discovered that EBNA3C interacts with the lysine demethylase KDM2B and that this interaction is important for its transcriptional repressive function. The findings in this study provide new insights into the mechanism used by the oncoprotein EBNA3C to repress cellular target genes.


  • Open Access

    Epstein-Barr virus nuclear protein EBNA3C directly induces expression of AID and somatic mutations in B cells

    by Jens S. Kalchschmidt, Rachael Bashford-Rogers, Kostas Paschos, Adam C.T. Gillman, Christine T. Styles, Paul Kellam, Martin J. Allday

    Activation-induced cytidine deaminase (AID), the enzyme responsible for induction of sequence variation in immunoglobulins (Igs) during the process of somatic hypermutation (SHM) and also Ig class switching, can have a potent mutator phenotype in the development of lymphoma. Using various Epstein-Barr virus (EBV) recombinants, we provide definitive evidence that the viral nuclear protein EBNA3C is essential in EBV-infected primary B cells for the induction of AID mRNA and protein. Using lymphoblastoid cell lines (LCLs) established with EBV recombinants conditional for EBNA3C function, this was confirmed, and it was shown that transactivation of the AID gene (AICDA) is associated with EBNA3C binding to highly conserved regulatory elements located proximal to and upstream of the AICDA transcription start site. EBNA3C binding initiated epigenetic changes to chromatin at specific sites across the AICDA locus. Deep sequencing of cDNA corresponding to the IgH V-D-J region from the conditional LCL was used to formally show that SHM is activated by functional EBNA3C and induction of AID. These data, showing the direct targeting and induction of functional AID by EBNA3C, suggest a novel role for EBV in the etiology of B cell cancers, including endemic Burkitt lymphoma.


  • Open Access

    EBNA3C Directs Recruitment of RBPJ (CBF1) to Chromatin during the Process of Gene Repression in EBV Infected B Cells

    by Jens S. Kalchschmidt, Adam C. T. Gillman, Kostas Paschos, Quentin Bazot, Bettina Kempkes, Martin J. Allday

    It is well established that Epstein-Barr virus nuclear antigen 3C (EBNA3C) can act as a potent repressor of gene expression, but little is known about the sequence of events occurring during the repression process. To explore further the role of EBNA3C in gene repression–particularly in relation to histone modifications and cell factors involved–the three host genes previously reported as most robustly repressed by EBNA3C were investigated. COBLL1, a gene of unknown function, is regulated by EBNA3C alone and the two co-regulated disintegrin/metalloproteases, ADAM28 and ADAMDEC1 have been described previously as targets of both EBNA3A and EBNA3C. For the first time, EBNA3C was here shown to be the main regulator of all three genes early after infection of primary B cells. Using various EBV-recombinants, repression over orders of magnitude was seen only when EBNA3C was expressed. Unexpectedly, full repression was not achieved until 30 days after infection. This was accurately reproduced in established LCLs carrying EBV-recombinants conditional for EBNA3C function, demonstrating the utility of the conditional system to replicate events early after infection. Using this system, detailed chromatin immunoprecipitation analysis revealed that the initial repression was associated with loss of activation-associated histone modifications (H3K9ac, H3K27ac and H3K4me3) and was independent of recruitment of polycomb proteins and deposition of the repressive H3K27me3 modification, which were only observed later in repression. Most remarkable, and in contrast to current models of RBPJ in repression, was the observation that this DNA-binding factor accumulated at the EBNA3C-binding sites only when EBNA3C was functional. Transient reporter assays indicated that repression of these genes was dependent on the interaction between EBNA3C and RBPJ. This was confirmed with a novel EBV-recombinant encoding a mutant of EBNA3C unable to bind RBPJ, by showing this virus was incapable of repressing COBLL1 or ADAM28/ADAMDEC1 in newly infected primary B cells. The Epstein-Barr nuclear protein EBNA3C is a well-characterised repressor of host gene expression in B cells growth-transformed by EBV. It is also well established that EBNA3C can interact with the cellular factor RBPJ, a DNA-binding factor in the Notch signalling pathway conserved from worms to humans. However, prior to this study, little was known about the role of the interaction between these two proteins during the repression of host genes. We therefore chose three genes–the expression of which is very robustly repressed by EBNA3C –to explore the molecular interactions involved. Hitherto these genes had not been shown to require RBPJ for EBNA3C-mediated repression. We have described the sequence of events during repression and challenge a widely held assumption that if a protein interacts with RBPJ it would be recruited to DNA because of the intrinsic capacity of RBPJ to bind specific sequences. We show that interaction with RBPJ is essential for the repression of all three genes during the infection of B cells by EBV, but that RBPJ itself is only recruited to the genes when EBNA3C is functional. These data suggest an unexpectedly complex interaction of multiple proteins when EBNA3C prevents the expression of cellular genes.